Becton Dickinson & Co. Rating Increased to Neutral at Merrill Lynch (BDX)
Becton Dickinson & Co. (NYSE:BDX) was upgraded by equities researchers at Merrill Lynch to a “neutral” rating in a research report issued on Tuesday, Stock Ratings News reports.
Becton Dickinson & Co. (NYSE:BDX) traded up 1.44% on Tuesday, hitting $111.03. The stock had a trading volume of 1,214,211 shares. Becton Dickinson & Co. has a 52-week low of $79.87 and a 52-week high of $110.94. The stock has a 50-day moving average of $108.3 and a 200-day moving average of $103.2. The company has a market cap of $21.550 billion and a P/E ratio of 16.85.
Becton Dickinson & Co. (NYSE:BDX) last announced its earnings results on Tuesday, November 5th. The company reported $1.52 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.46 by $0.06. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. During the same quarter last year, the company posted $1.42 earnings per share. Becton Dickinson & Co.’s revenue was up 6.8% compared to the same quarter last year. Analysts expect that Becton Dickinson & Co. will post $6.21 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Bank of America Corp. upgraded shares of Becton Dickinson & Co. from an “underperform” rating to a “neutral” rating in a research note to investors on Tuesday. They now have a $95.00 price target on the stock, down previously from $117.00. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Becton Dickinson & Co. in a research note to investors on Sunday, November 17th. They now have a $120.00 price target on the stock. Finally, analysts at Argus raised their price target on shares of Becton Dickinson & Co. from $115.00 to $125.00 in a research note to investors on Tuesday, November 12th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $110.04.
Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.